Authors’ Reply to Moura et al.: “Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk”

Detalles Bibliográficos
Autores principales: Rajasimhan, Suraj, Pamuk, Omer, Katz, James D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211588/
https://www.ncbi.nlm.nih.gov/pubmed/33871805
http://dx.doi.org/10.1007/s40266-021-00856-4
_version_ 1783709495636000768
author Rajasimhan, Suraj
Pamuk, Omer
Katz, James D.
author_facet Rajasimhan, Suraj
Pamuk, Omer
Katz, James D.
author_sort Rajasimhan, Suraj
collection PubMed
description
format Online
Article
Text
id pubmed-8211588
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-82115882021-07-01 Authors’ Reply to Moura et al.: “Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk” Rajasimhan, Suraj Pamuk, Omer Katz, James D. Drugs Aging Letter to the Editor Springer International Publishing 2021-04-19 2021 /pmc/articles/PMC8211588/ /pubmed/33871805 http://dx.doi.org/10.1007/s40266-021-00856-4 Text en © This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Letter to the Editor
Rajasimhan, Suraj
Pamuk, Omer
Katz, James D.
Authors’ Reply to Moura et al.: “Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk”
title Authors’ Reply to Moura et al.: “Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk”
title_full Authors’ Reply to Moura et al.: “Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk”
title_fullStr Authors’ Reply to Moura et al.: “Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk”
title_full_unstemmed Authors’ Reply to Moura et al.: “Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk”
title_short Authors’ Reply to Moura et al.: “Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk”
title_sort authors’ reply to moura et al.: “safety of janus kinase inhibitors in older patients: a focus on the thromboembolic risk”
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211588/
https://www.ncbi.nlm.nih.gov/pubmed/33871805
http://dx.doi.org/10.1007/s40266-021-00856-4
work_keys_str_mv AT rajasimhansuraj authorsreplytomouraetalsafetyofjanuskinaseinhibitorsinolderpatientsafocusonthethromboembolicrisk
AT pamukomer authorsreplytomouraetalsafetyofjanuskinaseinhibitorsinolderpatientsafocusonthethromboembolicrisk
AT katzjamesd authorsreplytomouraetalsafetyofjanuskinaseinhibitorsinolderpatientsafocusonthethromboembolicrisk

Ejemplares similares